Full List Of Stories
US close: Markets finish higher as investors keep eye on yields
US stocks finished higher on Wednesday, as investors appeared to shrug off ongoing trade fears and a flashing recession indicator in focus.
Webis subsidiary renews Cal Expo harness racing licence
Pool wagering specialist Webis Holdings announced on Wednesday that its US-based advanced deposit wagering business, WatchandWager, has been granted a renewal of its license to conduct harness racing at Cal Expo by the California Horse Racing Board, which was planned to run until 25 April 2020.
Mike Barker installed as finance chief at Tissue Regenix
Regenerative medical devices company Tissue Regenix Group announced the appointment of Mike Barker as its chief financial officer on Wednesday.
President Energy pivots focus to gas amid Argentina oil price fix
President Energy updated the market on recent activities in Argentina on Wednesday, reporting that the country’s government had recently issued a time-limited decree in an attempt to temporarily control prices at the fuel pumps for end consumers.
Attis secures third oilfield services contract
Attis Oil and Gas has secured its third oilfield service contract, providing regulatory testing and reporting services for 825 wells in the Texas Panhandle, it announced on Wednesday, bringing the total wells now under contract, with three separate operating companies, to 1,812.
Gatwick Airport kicks off process to bring standby runway into use
Gatwick Airport has formally launched the process to bring its standby runway into routine use, by submitting a notice to the Planning Inspectorate of its intention to apply for development permission.
Evgen Pharma completes patient study visits in 'SAS' phase 2 trial
Clinical stage drug development company Evgen Pharma announced on Wednesday that the last study visit for the last patient entered in the double-blind, placebo-controlled ‘SAS’ phase 2 clinical trial has taken place.
Collagen Solutions on track to meet full-year expectations
Biomaterials and regenerative medicines manufacturer Collagen Solutions said it remained positive about its outlook on Wednesday, telling shareholders it was “on track” with its key initiatives for the year, following its successful fundraise in June and momentum from the last financial year.
Avanti Communications narrows losses as it works towards positive earnings
Satellite data communications provider Avanti Communications Group reported adjusted revenues of $30. 2m (£24. 72m) in its first half results on Wednesday, rising from $25. 6m year-on-year.
Grafenia losses widen as it works towards EBITDA breakeven
Grafenia reported an improvement in its full-year revenue on Wednesday, to £15. 96m from £14. 63m, while its gross profit was ahead marginally at £8. 55m from £8. 34m.
Asia report: Markets struggle for direction as traders watch bond markets
Markets in Asia finished mixed on Wednesday, as investors struggled to find direction following another inversion of Treasury yield curves in the United States overnight.
Earnings rise as Bisichi Mining sees improved demand for coal
Bisichi Mining reported an improvement in earnings in its half-year results on Wednesday, with EBITDA rising to £5. 7m from £5. 2m year-on-year, and adjusted EBITDA growing to £5. 6m from £5. 3m.
Symphony International net asset value rises as it diversifies portfolio
Asia-focussed consumer business investor Symphony International Holdings reported an unaudited net asset value of $560. 38m (£459. 01m) in its half-year results on Wednesday, which was 13. 7% higher than the end of the 2018 financial year.
Chaarat Gold releases promising drilling results from Tulkubash
Armenia and Kyrgyz Republic-focussed gold mining company Chaarat Gold Holdings released further drilling results from its ongoing 2019 exploration and drilling programme at its Tulkubash oxide gold development project in the Kyrgyz Republic on Wednesday.
Arix Bioscience swings to loss ahead of portfolio milestones
Biotechnology-focussed venture capital company Arix Bioscience reported a net asset value of £231. 8m in its half-year results on Wednesday, down from £270. 2m at the end of the 2018 financial year, equating to 171p per share, down from 200p per share.
AstraZeneca upbeat on progress with 'Fasenra' and 'Breztri Aerosphere'
AstraZeneca announced on Wednesday morning that the US Food and Drug Administration (FDA) has granted ‘Orphan Drug Designation’ to ‘Fasenra’ (benralizumab), for the treatment of eosinophilic oesophagitis (EoE).